The FDA issued a warning letter to TXP Innovations LLC (dba Tex Peptides) after reviewing its website in July 2026 and finding it marketed unapproved injectable peptide drugs, including semaglutide, tirzepatide, retatrutide, SS-31 (elamipretide), tesamorelin, and PT-141 (bremelanotide). The agency deemed these unapproved new drugs under section 505(a) of the FD&C Act. The letter warns that continued violations could trigger seizure or injunction. It underscores FDA's ongoing crackdown on unapproved peptide products sold directly to consumers online.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.